STELLA PHARMA
NEWS

March 14th, 2024

Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma

Our company provides the boron drug for BNCT (Boron Neutron Capture Therapy), w……

READ MORE

March 4th, 2024

Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer

The results regarding safety and effectiveness of our product Borofalan(10B), u……

READ MORE

January 11th, 2024

Investigator-initiated Phase I BNCT clinical trial for newly diagnosed glioblastoma

We would like to announce that Phase I clinical trial for newly diagnosed gliob……

READ MORE

December 25th, 2023

Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma

Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……

READ MORE